Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Discussions on Health Crisis Management Agency Comes after COVID-19 Master Plan: Minister
October 18, 2021
- Japan Govt Unveils Outline of COVID-19 Responses, Eyes Oral Drug Rollout by Year-End
October 18, 2021
- Chuikyo OKs MHLW Proposal on CEA Price Adjustments, Analysis Team Set-Up
October 18, 2021
- COVID-19 Vaccine Label Revised to Warn of Myocarditis Risk in Young Men
October 18, 2021
- MHLW’s Unapproved Drug Council Determines High Needs for 7 Additional Indications for Fertility Treatments
October 14, 2021
- Drug Pricing Rules to Be Applied to Takeda’s Cell Therapy Alofisel: Chuikyo
October 14, 2021
- LDP League Hails Start of Panel Discussions on HPV Vaccine Recommendation
October 13, 2021
- Label Revisions Ordered for Ivermectin to Add Disturbed Consciousness to ADR List
October 13, 2021
- Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
October 12, 2021
- MHLW Orders Large-Scale Carcinogen Risk Inspections, Covering Almost All Drugs
October 11, 2021
- Choseido Hit by Biz Suspension of Up to 31 Days over Manufacturing Flaws
October 11, 2021
- LDP Seeks to Give More Power to Govt in Pandemic Response: Election Platform
October 11, 2021
- Kishida Poised to Revise Law to Boost Command Tower Functions for Emergency Control
October 11, 2021
- Nordic Restriction on Moderna Jab Won’t Affect Japan Inoculation Program: Minister
October 11, 2021
- Japan Clinches Deal for 120 Million Extra Pfizer Vaccine Doses
October 8, 2021
- Senior Vice Minister Yamamoto, Parliamentary Secretary Shimamura Responsible for Healthcare
October 8, 2021
- MHLW Publishes Application Statuses for Infertility Treatments
October 7, 2021
- Atsushi Koga, Hiroshi Yamamoto Named Senior Vice Health Ministers
October 7, 2021
- New Digital, Administrative Reform Minister Set to Break Silos, Propel Healthcare Revamp
October 6, 2021
- Economic Security Chief Vows to Beef Up Vaccine Development, Manufacturing in Japan
October 6, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…